Abstract
The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.
Keywords: Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer
Letters in Drug Design & Discovery
Title: Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies
Volume: 4 Issue: 2
Author(s): Joesph Mikhael and Hong Chang
Affiliation:
Keywords: Proteasome inhibitor, Bortezomib, Multiple myeloma, Clinical trial, Cancer
Abstract: The proteasome is a multicatalytic proteinase complex that is responsible for protein turnover through the ubiquitin-proteasome pathway. Bortezomib is the first drug to act as a proteasome inhibitor, and has yielded impressive anticancer effects in phase III trials in multiple myeloma. Its role in other hematological malignancies is being evaluated. Proteasome inhibition, therefore, represents a novel mechanism for anticancer therapy.
Export Options
About this article
Cite this article as:
Mikhael Joesph and Chang Hong, Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies, Letters in Drug Design & Discovery 2007; 4 (2) . https://dx.doi.org/10.2174/157018007779422541
DOI https://dx.doi.org/10.2174/157018007779422541 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Novel Pharmacodynamic Approach to Assess Obatoclax (GX15-070) and Bortezomib (BTZ) Synergism in Non-Hodgkin’s Lymphoma
Clinical Cancer Drugs New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Mini-Reviews in Medicinal Chemistry Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
CNS & Neurological Disorders - Drug Targets Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Current Pharmaceutical Design A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Thiopurine Immunomodulators in Ulcerative Colitis: Moving Forward with Current Evidence
Current Drug Targets Targeting the Epidermal Growth Factor Pathway as Therapy for Glioblastoma
Current Cancer Therapy Reviews In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Current Drug Targets